1. Agencies & Vendors

Four Ways Digital Intake Can Transform Patient Support Programs, Overcome Access Barriers, and Improve Outcomes

Written by Posted on Less than 0 min read

Today’s guest post comes from Michael Carr, Group Vice President, CoAssist Pharmacy at AssistRx.

Michael discusses the challenges that patients and healthcare providers face during the prescription intake and enrollment process. He outlines four key features of solutions that improve digital intake.

To learn about AssistRx’s digital intake technologies, download their case study: Digital Intake for More Meaningful Patient and HCP Interactions.

Read on for Michael’s insights.

Read more »

Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Data & Insights

The Battle for Oncology Margin: How Private Equity Enables Vertical Integration by Pharmaceutical Wholesalers

In case you haven’t noticed, private equity firms have displaced hospitals and health systems as the major acquirers of community oncology practices. These financial firms have assembled significant oncology practice management companies that are primed for purchase by drug channel participants. Below, I review recent M&A trends and then examine the strategic objectives behind the […]
2 min read
0
  1. Trends & External Forces

Value-Based Care Summit

Value-Based Care Summit Accelerating Healthcare’s Shift in the Move from Volume to Value In-Person Event January 26-27, 2023 View Original Article Data & Insights Health & Wellness Predictions and Forecasts Drug Channels Member since December 11, 2020 Loading + Follow Following Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution […]
< 1 min read
0
  1. Media & Marketing

Drug Channels News Roundup, November 2023: My $0.02 on Express Scripts’ Cost-Based Pricing, Mark Cuban vs. PBMs, Dual-WAC Strategies, Pharmacy Shakeout, and Adam vs. Rocky

I hope everyone enjoyed the Thanksgiving holiday. Now that you’ve stretched your stomach, it’s time to stretch your mind with some food for thought. In this issue: A reality check on Express Scripts’ purported “cost-based” pharmacy network Mark Cuban explains how and why the PBM market will change Why two drug prices are better than […]
2 min read
0
  1. Department: HBC

Behind the GoodRx-Express Scripts Partnership: How PBMs Profit from Discount Cards in Pharmacy Benefits (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Friday’s webinar will include my latest thoughts on a key trend discussed in todays rerun: how plan sponsors are incorporating patient-paid prescriptions—cash-pay prescriptions and discount cards—within pharmacy benefits. Click […]
2 min read
0
  1. Data & Insights

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2023. Time for Drug Channels’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes the following 10 […]
2 min read
0
  1. Agencies & Vendors

Improve Access, Affordability, and Brand Performance With GoodRx’s Point-of-Sale Rebate Programs

Today’s guest post comes from Jim Longley, Head of Commercial, Pharma Manufacturer Solutions at GoodRx. Jim discusses GoodRx Assist, a point-of-sale (POS) rebate program designed to help cash-paying patients start and stay on brand-name medication. Click here to learn more about GoodRx Assist. Read on for Jim’s insights. Read more » Copyright © 2006-2023 Pembroke […]
2 min read
0
  1. Trends & External Forces

Medicare Part D in 2024: Smaller Pharmacies Abandon Preferred Pharmacy Networks

In a previous article, I highlighted the largest pharmacy chains that will participate in the 2024 Medicare Part D prescription drug plans (PDP). Today, I update DCI’s exclusive analysis of how smaller pharmacies will participate as preferred cost sharing pharmacies via the pharmacy services administrative organizations (PSAOs) that represent them in negotiations with plans. As […]
2 min read
0
  1. Media & Marketing

The Drug Discount Ecosystem’s “Mission Critical”

Today’s guest post comes from Vishali Amin, Chief of Staff to the Office of the President and Senior Director of Customer Success at Kalderos. Vishali discusses the persistent challenges of duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program. The Inflation Reduction Act of 2022 will further complicate duplicate discount […]
2 min read
0
  1. Media & Marketing

A Clear Path to Education Affordability Requires Meeting Patients Where They Are

Today’s guest post comes from Kristina Crockett, VP of Product Management at CoverMyMeds. Kristina shares the story of a patient who cut pills in half to extend her prescriptions. Unfortunately, this patient didn’t know about manufacturer affordability programs. In this article, Kristina reviews how brands can help patients make connections that address medication affordability challenges, […]
2 min read
0
  1. Data & Insights

The Four Key Factors to Evaluate When Insourcing vs. Outsourcing Patient Support Programs

Today’s guest post comes from Josh Marsh, Vice President and General Manager of Sonexus™ Access and Patient Support at Cardinal Health. Josh discusses factors that drive manufacturers to insource versus outsource patient support services. He shares data from a Cardinal Health survey of biopharmaceutical companies and offers four factors to consider when evaluating your patient […]
2 min read
0
  1. Trends & External Forces

CVS, Walgreens, and Walmart Keep Position in 2023 Part D Preferred Networks—While Kroger Bails Over its Express Scripts Blowup

In Preferred Pharmacy Networks in 2023’s Medicare Part D Plans: Cigna, CVS Health, Humana, UnitedHealthcare, WellCare, and More, I highlighted how those networks have taken over the world of stand-alone Medicare Part D prescription drug plans (PDP) and become a major presence in Medicare Advantage prescription drug (MA-PD) plans. Today, I examine the seven largest […]
5 min read
0
  1. Media & Marketing

Four Ways for Field Teams to Tackle Drug Utilization Management and Optimize Patient Access

Today’s guest post comes from Patrick Leary, Chief Commercial Officer at Phil, Inc. Patrick describes how barriers to medication access affect manufacturers and patients. He offers four tactics that can help field teams unlock coverage for patients. To learn more about Phil’s access and commercialization solutions, download their free whitepaper, Modernize the Patient Access Experience: […]
< 1 min read
0
  1. Media & Marketing

The Warped Incentives Behind Amgen’s Humira Biosimilar Pricing–And What We Can Learn from Semglee and Repatha (rerun)

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. So far, it appears that PBMs are neither preferring Amgen’s Humira biosimilar nor embracing the low-list/low-rebate version. In February, AbbVie stated that U.S. Humira sales would be decline by about […]
3 min read
0
  1. Trends & External Forces

The Drug Discount Ecosystem Needs Clarity in 2024 and Beyond

Today’s guest post comes from Gavin Magaha, Senior Director of Value Delivery at Kalderos. Gavin discusses the problems manufacturers face in accessing and standardizing drug discount data. These data are necessary to avoid duplicate discounts and comply with regulatory requirements. To learn more about how the Inflation Reduction Act adds to challenges of drug discount […]
2 min read
0
  1. Technology & Innovation

Technology’s New Approach: One Gateway to Deliver Comprehensive Patient Support Services

Today’s guest post comes from Derek Berven, Senior Director of Software Engineering at AssistRx. Derek explains how to streamline patient support services with a modular, scalable technology solution. He then discusses Advanced Gateway, a technology that integrates patient, provider, and manufacturer services. Click here to learn more about how AssistRx’s Advanced Gateway can impact patient […]
2 min read
0
  1. Data & Insights

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers

Time for Drug Channels’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes the following 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB. You can find links to each company’s data below. When rebates and discounts were factored in, brand-name drug prices […]
3 min read
0
  1. Data & Insights

Surprising Data on Employer-PBM Rebate Pass-Through Arrangements in 2023 (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2024 live video webinar. Click here to see the original post from August 2023. Something to consider while you review today’s rerun: The Lower Costs, More Transparency Act (H.R. 5378), which the U.S. House of Representatives passed yesterday, contains new […]
3 min read
0
  1. Trends & External Forces

Available for Preorder: The 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 10, 2023, Drug Channels Institute will release 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our fourteenth edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. 9 chapters, 300+ pages, 163 exhibits, 600+ endnotes: There is nothing else available that comes close […]
3 min read
0
  1. Department: HBC

The Top Pharmacy Benefit Managers of 2022: Market Share and Trends for the Biggest Companies

In 2022, the PBM market remained highly consolidated—although there were some intriguing share shifts among the largest players. Below, you’ll find Drug Channels Institute’s latest estimates of pharmacy benefit manager (PBM) market share based on equivalent prescription claims. I also provide commentary on recent market developments and offer some helpful tips for interpreting the figures. […]
2 min read
0
  1. Media & Marketing

DCI’s Top 15 Specialty Pharmacies of 2022: Five Key Trends About Today’s Marketplace

In Drug Channels Institute’s list of the top 15 pharmacies of 2022, we show that central-fill, mail pharmacies operated by large PBMs and health insurers have displaced retail chains as the largest prescription drug dispensers by revenues. To complement that broader ranking, we rummaged around our DreamHouse to update our exclusive list of the top […]
2 min read
0
Next